Clearside Biomedical To Report Efficacy And Safety Results In Non-Infectious Uveitis Using A Single Suprachoroidal Injection Of Triamcinolone Acetonide At 2015 ARVO Meeting

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 1/2 clinical trial will be presented at the 2015 Annual Meeting of the Association for Research and Vision in Ophthalmology (ARVO), May 3-7, 2015, in Denver, CO.

Help employers find you! Check out all the jobs and post your resume.